Werewolf Therapeutics Inc

NASDAQ:HOWL USA Biotechnology
Market Cap
$42.24 Million
Market Cap Rank
#22927 Global
#8054 in USA
Share Price
$0.87
Change (1 day)
+7.30%
52-Week Range
$0.55 - $2.19
All Time High
$20.31
About

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more

Werewolf Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2024: 0.87%

Werewolf Therapeutics Inc (HOWL) has an Asset Resilience Ratio of 0.87% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$1.22 Million
Cash + Short-term Investments
Total Assets
$140.04 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Werewolf Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Werewolf Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.22 Million 0.87%
Total Liquid Assets $1.22 Million 0.87%

Asset Resilience Insights

  • Limited Liquidity: Werewolf Therapeutics Inc maintains only 0.87% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Werewolf Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Werewolf Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Werewolf Therapeutics Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Werewolf Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points